Filing Analysis
Climb Bio, Inc. has entered into a new At-The-Market (ATM) offering agreement with Jefferies LLC to sell up to $100 million in common stock. Simultaneously, the company terminated a previous, unused ATM agreement with Oppenheimer & Co. Inc. that had a capacity of $22.35 million.
🚩 Red Flags
- Significant potential dilution: The $100 million offering capacity is substantial for a micro-cap company and may lead to significant share price dilution.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on June 12, 2026.
- The new ATM offering allows for the sale of common stock with an aggregate offering price of up to $100.0 million.
- Jefferies LLC will receive a commission of up to 3.0% of the gross sales price per share.
- Terminated a prior Equity Distribution Agreement with Oppenheimer & Co. Inc. effective June 11, 2026.
- No shares were sold under the previous Oppenheimer agreement ($22.35 million capacity) prior to its termination.
Climb Bio announced initial Phase 1b data for budoprutug, an anti-CD19 monoclonal antibody for primary immune thrombocytopenia (ITP). The data indicates the drug was generally well-tolerated with positive signs of B-cell depletion and platelet count increases in a heavily pretreated patient population.
📋 Key Facts
- Study (NCT07043946) evaluated three ascending doses (250mg, 500mg, 1000mg) of intravenous budoprutug.
- As of June 1, 2026, 15 patients were enrolled in the 250mg (n=6) and 500mg (n=9) cohorts.
- Patients were heavily pretreated with a median of 6 to 7.5 prior lines of therapy.
- In the 250mg cohort, B-cell levels were depleted by >90% by Week 4, and mean platelet count increased by 111,000 platelets/µL at Week 24.
- Four out of six patients in the 250mg cohort achieved durable platelet responses.
- No serious adverse events or treatment discontinuations due to adverse events were reported; all AEs were Grade 1 or 2.
- Additional data is expected by year-end 2026.
Climb Bio, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 5, 2026. The stockholders elected two directors, ratified the accounting firm, and approved an amendment to the 2021 Equity Incentive Plan, though they did not approve a change to the removal of directors for 'cause'.
🚩 Red Flags
- Stockholders rejected the proposal to amend the Certificate of Incorporation regarding the removal of directors for 'cause', indicating potential friction between management/board and a segment of shareholders.
📋 Key Facts
- Elected Alexander (Bo) Cumbo and Douglas Williams, Ph.D. to the Board for three-year terms expiring in 2029.
- Ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Approved the 2021 Plan Amendment to include prefunded warrants in the calculation of the annual share pool increase.
- Failed to approve an amendment to the Certificate of Incorporation regarding the removal of directors for 'cause'.
Climb Bio announced positive preliminary Phase 1 safety data and translational pharmacometric modeling for CLYM116, an anti-APRIL monoclonal antibody. The data indicates the drug is generally well-tolerated in healthy volunteers and suggests potential for less-frequent dosing.
🚩 Red Flags
- Forward-looking statements explicitly mention the need for 'raising the substantial additional capital needed' to continue development of CLYM116 and other candidates.
📋 Key Facts
- Preliminary safety data from 49 healthy volunteers receiving single doses up to 320 mg showed no serious adverse events or dose-limiting toxicities.
- All observed adverse events were mild to moderate (Grade 1-2), transient, and self-resolving.
- Translational modeling from non-human primate (NHP) data suggests dose-dependent IgA suppression and potential for reduced dosing frequency.
- Phase 1 studies are being conducted in Australia and China (via partner Beijing Mabworks Biotech).
- Mabworks expects to initiate dosing in IgA nephropathy (IgAN) patients in the Phase 2 portion of its study in Q3 2026.
Climb Bio, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results reported for the quarter ended March 31, 2026
- The report was filed on May 7, 2026
- Information was furnished under Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the detailed press release regarding the financial performance
Climb Bio, Inc. (CLYM) hosted a virtual investor event on May 5, 2026, to provide updates on its clinical-stage anti-CD19 monoclonal antibody, budoprutug. The presentation focused on the drug's development for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.
📋 Key Facts
- The investor event was held on May 5, 2026, at 8:00 a.m. ET.
- The primary focus is budoprutug, a clinical-stage anti-CD19 monoclonal antibody.
- Target indications include primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus.
- The filing includes a press release (Exhibit 99.1) and a formal investor presentation (Exhibit 99.2).
Climb Bio, Inc. entered into a securities purchase agreement for a $110 million private placement (PIPE) of common stock and pre-funded warrants at $9.50 per share. The transaction involves significant participation from RA Capital Management and is intended to fund the company's late-stage clinical development programs.
🚩 Red Flags
- Significant dilution to existing shareholders through the issuance of approximately 11.59 million shares/equivalents.
- Related-party transaction involving RA Capital Management, an existing major shareholder/affiliate.
- The offering is a private placement (PIPE) which may involve registration rights that create future selling pressure.
📋 Key Facts
- Aggregate gross proceeds of approximately $110.0 million before fees.
- Issuance of 9,481,000 shares of common stock and 2,106,000 pre-funded warrants.
- Purchase price of $9.50 per share (and $9.4999 per pre-funded warrant).
- RA Capital Management is a lead investor, with a beneficial ownership cap set at 33.0%.
- Company committed to filing a resale registration statement within 45 days of closing.
- Placement agents include Leerink Partners, Piper Sandler, and Raymond James.
Climb Bio, Inc. announced that Cindy Driscoll, Senior Vice President of Finance and Principal Accounting Officer, will depart the company on April 30, 2026. Dr. Susan Altschuller, the current Chief Financial Officer, will assume the additional responsibilities of Principal Accounting Officer.
🚩 Red Flags
- Departure of the Principal Accounting Officer (PAO), which can sometimes signal internal control transitions or disagreements, though characterized here as mutual.
- Consolidation of the PAO and CFO roles under a single individual.
📋 Key Facts
- Cindy Driscoll's separation from the company is effective April 30, 2026.
- Dr. Susan Altschuller, the current CFO, will take over as Principal Accounting Officer (PAO) on the separation date.
- Dr. Altschuller has served as CFO since October 2025 and has prior CFO experience at Cerevel Therapeutics and ImmunoGen.
- The company stated the separation was a mutual agreement.
- No changes were made to Dr. Altschuller's compensatory arrangements in connection with the appointment.
Climb Bio, Inc. reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The results were furnished via a press release as part of a standard Item 2.02 filing.
📋 Key Facts
- Financial results for the quarter and year ended December 31, 2025, were announced on March 5, 2026.
- The information was furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- The filing includes Exhibit 99.1, the press release detailing the financial performance.